➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Moodys
Harvard Business School
Mallinckrodt
Colorcon

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

Onabotulinumtoxina - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for onabotulinumtoxina

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Walter Reed National Military Medical CenterPhase 2
Amir Moradi MD, MBAPhase 4
University of Wisconsin, MadisonPhase 4

See all onabotulinumtoxina clinical trials

Recent Litigation for onabotulinumtoxina

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
In re: Aoki2013-07-30

See all onabotulinumtoxina litigation

PTAB Litigation
PetitionerDate
2017-02-21

See all onabotulinumtoxina litigation

Pharmacology for onabotulinumtoxina

Company Disclosures: US Patents for onabotulinumtoxina

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial The Regents of the University of Colorado (Boulder, CO) 2017-07-15 RX company
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for onabotulinumtoxina

These patents were identified by searching patent claims

Supplementary Protection Certificates for onabotulinumtoxina

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008901655481 Italy   Start Trial PRODUCT NAME: NEUROTOSSINA DI CLOSTRIDIUM BOTULINUM DI TIPO A (150 KD) PRIVA DI PROTEINE COMPLESSATE(XEOMIN); AUTHORISATION NUMBER(S) AND DATE(S): 838, 20080409;57093.00.00, 20050531
2008000043 Germany   Start Trial PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
1658858/01 Switzerland   Start Trial FORMER OWNER: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, US
13C/047 Belgium   Start Trial PRODUCT NAME: TOXINE BOTULIQUE TYPE A; AUTHORISATION NUMBER AND DATE: 263103-5/2012 20130128
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
McKinsey
Colorcon
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.